Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA9 | Q16790 | 5/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30556213 | 0.85 | CA1 (0.38) | CA12CA1CA9DRD2PREP | |
| SCHEMBL29787984 | 0.79 | HTT (0.35) | CA12CA1CA9DRD2PREP | |
| SCHEMBL5716668 | 0.79 | CA1 (0.36) | CA12CA1CA9CA2CA4 | |
| SCHEMBL24167590 | 0.78 | CA1 (0.54) | CA12CA1CA9DRD2CA2 | |
| SCHEMBL2329763 | 0.78 | TSHR (0.44) | CA12CA1CA9PREP | |
| SCHEMBL1863318 | 0.78 | HTR7 (0.39) | CA12CA1CA9 | |
| SCHEMBL29497318 | 0.78 | HTR7 (0.39) | CA12CA1CA9 | |
| SCHEMBL30556207 | 0.78 | TSHR (0.44) | CA12CA1CA9PREP | |
| SCHEMBL2500390 | 0.76 | ALDH1A1 (0.39) | — | |
| SCHEMBL9562554 | 0.76 | HTR7 (0.38) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366687-B1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | NAT UNIV CORP TOTTORI UNIV (JP) | 2020-04-29 | — | — | EP | claimed |
| US-10597398-B2 | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2020-03-24 | — | — | US | claimed |
| US-20190055249-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2019-02-21 | — | — | US | claimed |
| EP-3366687-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | National University Corporation Tottori University (JP) | 2018-08-29 | — | — | EP | claimed |
| EP-3366687-B1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | NAT UNIV CORP TOTTORI UNIV (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10597398-B2 | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190055249-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3366687-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | National University Corporation Tottori University (JP) | 2018-08-29 | — | — | EP | disclosed |
| WO-1995011215-A1 | NON-STEROID ANDROGEN RECEPTOR ANTAGONISTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597398-B2 | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis | HDGF, SHC1, HGF | CA12 4107/4885CA1 4677/4885CA9 3704/4885 |
| US-20190055249-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | HDGF, SHC1, HGF | CA12 4107/4885CA1 4677/4885CA9 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.